Orforglipron ORFO

An experimental weight-loss pill (rather than an injection) from a major drug company, in late-stage human trials for obesity and diabetes. Trial results show substantial weight loss similar to injectable drugs in its class, with the added convenience of being a pill, and it's expected to likely gain approval.

Also known as LY3502970

Effects Lose fat

Routes Oral

Legal status Unapproved / investigational

WADA Not listed

Molecular Structure of C₄₈H₄₈F₂N₁₀O₅

Drag to rotate · scroll to zoom

Chemistry

Formula: C48H48F2N10O5
Molar mass: 883.0
CAS: 2212020-52-3
PubChem CID: 137319706

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Approved dose (per most recent trials/regulatory filings): up to 36 mg once daily, titrated

Reported range Phase III trials: 3-36 mg once daily, titrated over several months

Route Oral

Frequency Once daily

Duration Chronic/ongoing (per approved or expected labeling)

An oral, non-peptide GLP-1 receptor agonist (Eli Lilly) that reported positive Phase III weight-management and diabetes results; regulatory review was ongoing/newly completed as of early 2026 in various markets, so confirm current approval status before publishing exact labeled dosing.

Where this comes from Published Phase III clinical trial data (Eli Lilly); regulatory filings

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.

Variants

Name	Abbr	Route	Notes
Orforglipron tablet	ORFO-T	Oral	Once-daily tablet with no food or water restrictions.